Trastuzumab Discount Agreements (Open House)
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Trastuzumab, ATC L01FD01
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or guaranteed volume. Agreements are non-exclusive and may be terminated if a regular procurement oc...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2026
- Non-exclusive discount agreements for Trastuzumab (ATC L01FD01) for AOK Bayern.
- Open house model: any eligible pharmaceutical company can join.
Show full summary
Open House non-exclusive discount agreements for pharmaceutical product Trastuzumab (ATC L01FD01) in Bavaria, Germany. All interested pharmaceutical companies meeting eligibility can join. Contract period 2024-12-01 to 2026-11-30. Submission possible any time until 2026-10-05.
Risks
No estimated value or guaranteed volume. Agreements are non-exclusive and may be terminated if a regular procurement oc...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer).
Administrative
- Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submit signed contract and annex listing relevant drugs.
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Trastuzumab Discount Agreements (Open House)
Non-exclusive discount agreements for Trastuzumab (ATC L01FD01) for pharmacies in Bavaria.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Trastuzumab, ATC L01FD01
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Oct 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 627571-2024
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or guaranteed volume. Agreements are non-exclusive and may be terminated if a regular procurement oc...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications